Coronavirus (COVID-19): visiting The Royal Marsden suspended

Coronavirus (COVID-19) latest: Visiting The Royal Marsden is still suspended, but we want to reassure our patients, their families and anyone worried about cancer during this difficult time that we are still delivering treatment - the hospital is open. Please see more information here about how we are keeping everyone safe.

Professor James Larkin

Consultant Medical Oncologist PhD FRCP F Med Sci

Specialism: Skin, Urology

Available at: Chelsea

Special interests:

  • melanoma
  • kidney cancer
  • novel therapies for melanoma and kidney cancer

Biography

Professor James Larkin is a Consultant Medical Oncologist specialising in the treatment of melanoma and cancers of the kidney.

Professor Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the Institute of Cancer Research leading to a PhD. Specialist training was completed at The Royal Marsden and he was appointed a Consultant in 2008.

His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies.

He is a past National Institute for Health Research (NIHR) National Specialty Lead for Early Phase Oncology Trials, as well as a past Chair of the NCRI Renal Cancer Clinical Studies Group, The Royal Marsden/ICR Committee for Clinical Research and the CRUK Clinical Research Monitoring Panel.  He is currently Vice Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at The Royal Marsden/ICR Biomedical Research Centre.  In 2018 he was elected as a Fellow of the Academy of Medical Sciences.  Since 2019 he has been Vice Chair of the Medical Oncology Specialist Advisory Committee for the Joint Royal Colleges of Physicians Training Board and in 2020 he was appointed as an NIHR Senior Investigator.

He serves as a senior clinical adviser to CRUK, as a medical advisor to the patient advocacy group Melanoma UK, as a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.

 

Clinical units